Skip to content
Calculator
Evidence: HighPeptideFDA ApprovedTripeptide analogueFDA-approved 2023 · DaybueRett syndrome

Trofinetide

The first approved treatment for Rett syndrome, an oral analogue of an IGF-1 fragment

Trofinetide is a synthetic analogue of glycine-proline-glutamate, the first three amino acids of IGF-1. Approved as Daybue in March 2023, it is the first treatment for Rett syndrome, taken by mouth twice a day.

Manufacturer's recommended dosing (FDA label): 5,000 mg (9–12 kg) up to 12,000 mg (50 kg or more), Twice daily, Oral or gastrostomy Details ↓

Overview

What is it?

Rett syndrome is a rare genetic neurodevelopmental disorder; the trials below enrolled girls and young women with it, from age 2 upward. Caregivers most often name communication as the ability they most want a treatment to help. Until 2023 there was no approved treatment for the disorder itself.

Trofinetide was built from a fragment of IGF-1: the tripeptide glycine-proline-glutamate, which in laboratory work affects how nerve connections function. In the 12-week phase 3 LAVENDER trial, 187 girls and young women with Rett syndrome received trofinetide or placebo; both co-primary measures, a caregiver behaviour questionnaire and a clinician's global rating, improved more on the drug, and so did a communication score. The FDA approved it as Daybue on March 10, 2023.

LAVENDER was the third randomised trial. Two smaller phase 2 studies came first: one in adolescent and adult women, where the higher 70 mg/kg dose met prespecified efficacy criteria, and one in 82 children and adolescents aged 5 to 15, where 200 mg/kg twice a day improved the behaviour questionnaire, a clinician's visual-analogue concern scale and the global improvement rating against placebo. The phase 3 dose built on that work and is set by body weight.

The effects were modest in size, and the main cost is gastrointestinal: diarrhoea affected about four in five patients in the trial. Its open-label extensions and a real-world study describe continued improvement and practical ways families manage the diarrhoea.

Approval has spread beyond the US: the European Medicines Agency authorised it as Daybue on August 20, 2026. In the US it is taken as an oral solution twice a day, by mouth or through a gastrostomy tube, at doses that reach 12 grams twice daily in heavier patients. The label warns about diarrhoea, which can lead to dehydration, and about weight loss, and recommends stopping laxatives before starting.

Since approval, routine use has filled in the picture. Pooled across three randomised trials of 276 patients, the gains on the behaviour questionnaire and clinician rating are real but small. In one large US clinic, three quarters of patients improved by caregiver report, and diarrhoea and vomiting were less common than in phase 3, which the clinicians put down to slow titration and individual dosing. Post-marketing reports point to the first month as the riskiest, with appetite and weight loss alongside diarrhoea. Use has extended to males and to atypical MECP2 cases that the trials did not include, and a powder that can be dissolved in less liquid gives the same blood levels as the ready-made solution, which matters for children fed by tube.

−4.9 vs −1.7
behaviour score change at 12 weeks
LAVENDER, 187 patients (2023) · PMID 37291210
~80%
diarrhoea in LAVENDER
mostly mild to moderate · PMID 40043705
Mar 10, 2023
FDA approval (Daybue)
first drug for Rett syndrome · Drugs@FDA
Aug 20, 2026
EU authorisation
EMA dataset · EMA medicines dataset
Science

Mechanism of Action

Trofinetide is a modified fragment of IGF-1 designed to act in the brain; how it improves Rett symptoms is not fully understood.

🧬

From IGF-1

It is a synthetic analogue of glycine-proline-glutamate, the N-terminal tripeptide of insulin-like growth factor 1, modified to last longer in the body.

🧠

Synaptic function

In laboratory work the parent tripeptide affects how nerve connections function, the rationale for testing it in Rett syndrome, a disorder of synaptic development.

⚖️

Exposure and response

In the paediatric phase 2 trial, improvements tracked drug exposure, which is why the label doses by body weight.

🍽

Gut effects

Diarrhoea and vomiting are the dominant side effects at therapeutic doses, so dosing guidance centres on managing them.

Evidence

Published Research

The studies behind trofinetide, read from their PubMed abstracts.

Human2023

LAVENDER phase 3, 187 patients

Over 12 weeks, the Rett Syndrome Behaviour Questionnaire improved by 4.9 points on trofinetide against 1.7 on placebo, and the clinician's global improvement score was 3.5 against 3.8 (lower is better); both co-primary end points were met, with effect sizes of 0.37 and 0.47. Diarrhoea affected 80.6% against 19.1%.

PMID: 37291210
Human2023

Communication in LAVENDER

A caregiver-rated communication score improved by 1.0 point more on trofinetide than placebo (effect size 0.43), and a clinician rating of non-verbal choice-making improved nominally; verbal communication did not change.

PMID: 38232652
Human2024

LILAC: 40-week extension

In 154 participants aged 5 to 21, behaviour scores improved by about 7 points from the original baseline by week 40; diarrhoea affected 74.7% and was the commonest reason for stopping (21.4%).

PMID: 38917793
Human2024

LILAC-2: 32 months

In 77 participants, behaviour scores had improved by 11.8 points from the original baseline at week 104; diarrhoea affected 53.2%, and 24 of 25 caregivers interviewed were satisfied with the benefits.

PMID: 39025065
Human2025

DAFFODIL: girls aged 2 to 4

In 15 young girls, weight-based dosing reached the target drug exposure; diarrhoea (80.0%) and vomiting (53.3%) were mostly mild or moderate, and clinician and caregiver ratings improved over about two years.

PMID: 40043705
Human2025

LOTUS: real-world use

Among 227 caregivers of patients prescribed trofinetide, 71% to 90% reported behavioural improvements over 12 months; doses were built up gradually, and diarrhoea was reported in 23% to 50% in the first weeks.

PMID: 40936177
Human2019

Phase 2 in 82 children and adolescents

Aged 5 to 15, randomised to placebo or 50, 100 or 200 mg/kg twice daily for 42 days; 200 mg/kg improved the Rett Syndrome Behaviour Questionnaire, a clinician concern scale and the global improvement score over placebo, and changes tracked exposure.

PMID: 30918097
Human2017

Phase 2 in adolescents and adults

35 and 70 mg/kg were well tolerated; the 70 mg/kg dose met prespecified efficacy criteria, though the trial was short, small and in advanced disease.

PMID: 28964591
Human2026

Clinic experience after approval

At the Children's Hospital of Philadelphia, 75.9% of treated patients improved in some way by caregiver report, especially engagement, communication and motor skills; 48.1% had diarrhoea and 16.7% vomiting, fewer than in phase 3, which the authors credit to titration and individualised dosing. Treated patients included males and atypical MECP2 cases.

PMID: 42111068
Human2026

Males with Rett syndrome

In US claims data, most males with Rett syndrome were untreated; those started on trofinetide had more epilepsy, gastrostomy and respiratory failure. About 70% stayed on it for at least six months and more than half for at least 17 months.

PMID: 42377739
Human2026

Post-marketing reports (FAERS)

Of 15,266 adverse event reports from 2,824 US patients, gastrointestinal disorders, above all diarrhoea, dominated; signals not on the label included decreased appetite, weight loss, viral gastroenteritis and irritability, and most events began in the first 30 days.

PMID: 41613782
Human2025

Doses for children aged 2 to 4

Population pharmacokinetic modelling showed that the weight-banded doses used in the DAFFODIL study, 5 g for 9 to under 12 kg and 6 g for 12 to under 20 kg, gave blood levels in the range known to be effective.

PMID: 39692837
Human2026

Powder against ready-made solution

In 38 healthy adults, a 12,000 mg dose gave equivalent blood levels whether taken as the ready-to-use 60 mL solution or as powder dissolved in 60 mL or only 25 mL of water.

PMID: 41678137
Review2024

Pooled randomised trials

Pooling three randomised trials (276 patients), trofinetide improved the caregiver-rated Rett Syndrome Behaviour Questionnaire by 3.46 points and the clinician's global impression by 0.35 points against placebo. Diarrhoea led to discontinuations and became a significant risk once the low-dose study was excluded.

PMID: 39020317
Animal2025

An Alzheimer's model in mice

In APP/PS1 mice, trofinetide improved cognition, reduced amyloid plaques, microglial activation and neuron loss, and in cells it cut inflammatory cytokines and apoptosis. It has not been tested in Alzheimer's disease in people.

PMID: 41269410
Dosing

Dosing Data

Trofinetide (Daybue) is taken twice daily as an oral solution, by mouth or gastrostomy tube, at a dose set by body-weight band.

The dose is set by the prescriber from the label's weight bands; diarrhoea is common and the label advises stopping laxatives beforehand and watching for dehydration and weight loss.
ProtocolDoseFrequencyDurationRoute
Label: by weight band Approved labelDaybue (trofinetide) oral solution US prescribing information (DailyMed set 67e6f2d9-21f6-466f-9def-826c6a4b8257, effective September 4, 2026)5,000 mg (9–12 kg) up to 12,000 mg (50 kg or more)Twice dailyOngoingOral or gastrostomy
Paediatric phase 2 (2019) Human studyPMID 3091809750, 100 or 200 mg/kgTwice daily42 daysOral

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

Grams, not micrograms
Daybue is a ready-to-use oral solution measured in millilitres from the label's weight table; there is nothing to reconstitute.
Open Calculator →
For Buyers

What a Buyer Needs to Know

What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.

What is sold

The approved product, as its label describes it:

  • Daybue and Daybue Stix (trofinetide solution and for solution): Oral solution: 200 mg/mL. For oral solution: 5,000 mg, 6,000 mg, or 8,000 mg per packet.

Source: Daybue and Daybue Stix (trofinetide solution and for solution) label, section 3 (DailyMed version 12, effective September 4, 2026).

Mixing a vial: a worked example

Nothing to mix: the label gives Daybue and Daybue Stix (trofinetide solution and for solution), ready to use.

Source: Daybue and Daybue Stix (trofinetide solution and for solution) label, sections 2, 3 and 16 (DailyMed version 12, effective September 4, 2026).

Storage before and after mixing

Before mixing or first use: “Store DAYBUE in an upright position refrigerated at 2°C to 8°C (36°F to 46°F).” “Store DAYBUE STIX packets at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F).” “Do not freeze.”

After mixing or first use: “Administer the prepared oral solution immediately; do not store for future use.” “Discard any prepared oral solution that is not immediately administered.”

Source: Daybue and Daybue Stix (trofinetide solution and for solution) label, sections 16 and 2 (DailyMed version 12, effective September 4, 2026).

How it is taken

As the approved label gives it: Oral or gastrostomy (Twice daily; Label: by weight band).

Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.

What to expect, and when

How long it stays in the body: a half-life of about 1.5 hours (effective, oral, healthy subjects). After about five half-lives almost none is left.

When effects appear: unknown; no source on this page gives a time to effect for Trofinetide. Results reported in the studies are under Published Research.

Source: half-life: Daybue prescribing information, section 12.3 (DailyMed set 67e6f2d9-21f6-466f-9def-826c6a4b8257, effective September 4, 2026; read October 3, 2026).

Side effects, and when to stop or get help

From the Side Effects section: Diarrhoea, in about four in five patients in the trials; Vomiting; Weight loss; Diarrhoea was the most common reason for stopping in the 40-week LILAC extension, where it affected 74.7%; Vomiting, especially in the youngest children (53.3% in DAFFODIL); Weight loss, which the label lists among its warnings. Full list and cautions ↓

When the label says to stop or get help:

  • Diarrhea: Most patients experience diarrhea during treatment with DAYBUE. Advise patients to stop laxatives before starting DAYBUE or DAYBUE STIX. If diarrhea occurs, patients should start antidiarrheal treatment, increase oral fluids, and notify their healthcare provider.

Source: Daybue and Daybue Stix (trofinetide solution and for solution) label, boxed warning and section 5 (DailyMed version 12, effective September 4, 2026); the Side Effects section below (“From the studies above”).

Interactions

  • sensitive oral CYP3A and/or P-gp substrates: trofinetide can raise their levels; closely monitor for adverse reactions when a small increase could be serious

Every peptide's record, with its source: the interaction matrix.

Source: Acadia. DAYBUE (trofinetide) US prescribing information, section 7. DailyMed version of September 4, 2026, read October 3, 2026.

Checking what you bought

Unknown: no published independent test of Trofinetide products is in our lab-results database yet, so how products sold under this name measure up is not known.

To read a certificate of analysis, paste it into the COA decoder; it checks the measured mass against Trofinetide's expected mass, 315.3 Da, from this entry's molecular data. Trust & Verification explains what independent testing can and cannot show.

Legal status

US: FDA Approved (Approved in the US as Daybue (trofinetide), NDA 217026, Acadia Pharmaceuticals, on March 10, 2023, for Rett syndrome in adults and children aged 2 years and older (Drugs@FDA via openFDA and the Daybue label, read October 3, 2026)). Sport: Not on the 2026 List.

Country by country ↓ · Regulatory tracker

Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.

Safety

Side Effects & Contraindications

Reported Side Effects

From the studies above.

● Diarrhoea, in about four in five patients in the trials
● Vomiting
● Weight loss
● Diarrhoea was the most common reason for stopping in the 40-week LILAC extension, where it affected 74.7%
● Vomiting, especially in the youngest children (53.3% in DAFFODIL)
● Weight loss, which the label lists among its warnings

Contraindications & Cautions

Warnings from the Daybue label (DailyMed, effective September 4, 2026).

● Diarrhoea: stop laxatives before starting and manage dehydration
● Weight loss: monitor weight
● Vomiting
● Tested athletes — see the Sport (WADA) row below
Questions

Frequently Asked Questions

?What is trofinetide?

A synthetic analogue of glycine-proline-glutamate, a three-amino-acid fragment of IGF-1, approved as Daybue for Rett syndrome in patients aged 2 and older.

?How well does it work?

In the 12-week phase 3 LAVENDER trial, behaviour and global improvement scores improved more than on placebo, with modest effect sizes of about 0.4 to 0.5.

?What is the main side effect?

Diarrhoea, which affected 80.6% of patients on trofinetide in LAVENDER against 19.1% on placebo.

?Is trofinetide approved in Europe?

Yes. The European Medicines Agency authorised Daybue on August 20, 2026.

?How much does trofinetide help?

In LAVENDER the behaviour score improved by 4.9 points against 1.7 on placebo over 12 weeks; the improvement was real but modest, and longer open-label studies describe further gains.

?Why is diarrhoea so common?

It affected about four in five patients in LAVENDER, mostly mild to moderate; families manage it with gradual dose increases and by stopping laxatives, as the label advises.

?Who can take trofinetide?

The US label covers adults and children aged 2 and older with Rett syndrome. The trials enrolled girls and women, because Rett syndrome mostly affects females; the youngest, aged 2 to 4, were studied in the small DAFFODIL trial.

?How quickly does it work?

In LAVENDER, differences from placebo were measured after 12 weeks; in the open-label extensions, behaviour scores kept improving to week 40 and beyond, though without a placebo group for comparison.

?Does it cure Rett syndrome?

No. It treats symptoms; in trials it improved caregiver-rated behaviour and communication measures modestly, and the underlying genetic cause is unchanged.

?How is trofinetide taken?

As an oral solution twice a day, morning and evening, by mouth or through a gastrostomy tube; the volume depends on body weight, from the label's weight table.

?What did families say in real-world use?

In the LOTUS survey of 227 caregivers of patients prescribed trofinetide, 71% to 90% reported behavioural improvements over 12 months; doses were usually built up gradually to manage diarrhoea. Surveys like this have no comparison group.

Bibliography

References

  1. [fda] US FDA, Drugs@FDA (openFDA): DAYBUE (trofinetide), NDA 217026, original approval March 10, 2023, prescription. Read October 3, 2026.
  2. [fda-pi] FDA. Daybue (trofinetide) oral solution US prescribing information (DailyMed set 67e6f2d9-21f6-466f-9def-826c6a4b8257, version 12, effective September 4, 2026). Read October 3, 2026.
  3. [other] EMA medicines dataset: Daybue (trofinetide), authorised August 20, 2026. Read October 5, 2026.
  4. [pubmed] Neul JL, et al. "Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study." Nat Med, 2023;29(6):1468-1475. PMID: 37291210.
  5. [pubmed] Neul JL, et al. "Trofinetide Treatment Demonstrates a Benefit Over Placebo for the Ability to Communicate in Rett Syndrome." Pediatr Neurol, 2024;152:63-72. PMID: 38232652.
  6. [pubmed] Percy AK, et al. "Trofinetide for the treatment of Rett syndrome: Results from the open-label extension LILAC study." Med, 2024;5(9):1178-1189.e3. PMID: 38917793.
  7. [pubmed] Percy AK, et al. "Trofinetide for the treatment of Rett syndrome: Long-term safety and efficacy results of the 32-month, open-label LILAC-2 study." Med, 2024;5(10):1275-1281.e2. PMID: 39025065.
  8. [pubmed] Percy AK, et al. "Results from the phase 2/3 DAFFODIL study of trofinetide in girls aged 2-4 years with Rett syndrome." Med, 2025;6(6):100608. PMID: 40043705.
  9. [pubmed] Cosand L, et al. "Real-world benefits and tolerability of trofinetide for the treatment of Rett syndrome: The LOTUS study." Dev Med Child Neurol, 2026;68(3):407-417. PMID: 40936177.
  10. [pubmed] Glaze DG, et al. "Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome." Neurology, 2019;92(16):e1912-e1925. PMID: 30918097.
  11. [pubmed] Glaze DG, et al. "A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Rett Syndrome." Pediatr Neurol, 2017;76:37-46. PMID: 28964591.
  12. [pubmed] Mohammed HE, et al. "Is trofinetide a future treatment for Rett syndrome? A comprehensive systematic review and meta-analysis of randomized controlled trials." BMC Med, 2024;22(1):299. PMID: 39020317.
  13. [pubmed] Prange EO, et al. "Clinical experience using trofinetide in Rett syndrome and related MECP2 diagnosis at the children's hospital of Philadelphia post approval." Front Neurol, 2026;17:1776146. PMID: 42111068.
  14. [pubmed] Rajagopalan K, et al. "Real-World Demographics, Clinical Characteristics, and Predictors of Persistence Among Males with Rett Syndrome Treated with Trofinetide." Adv Ther, 2026;43(10):4458-4472. PMID: 42377739.
  15. [pubmed] Yu X, et al. "Post-marketing safety concerns with trofinetide: a disproportionality analysis of the first therapeutic agent for Rett syndrome based on the FDA adverse event reporting system (FAERS)." Front Pharmacol, 2026;17:1643906. PMID: 41613782.
  16. [pubmed] Darwish M, et al. "Population Pharmacokinetics of Trofinetide in a Pediatric Population Aged 2-4 Years with Rett Syndrome." Adv Ther, 2025;42(2):1009-1025. PMID: 39692837.
  17. [clinical-trial] Darwish M, et al. "A Phase 1, Randomized, Open-Label Study to Assess the Bioequivalence of Trofinetide as a Ready-to-Use Oral Solution and Constituted Powder for Oral Solution in Healthy Adults." Adv Ther, 2026;43(4):1536-1551. PMID: 41678137.
  18. [pubmed] Chen M, et al. "Trofinetide Improves Cognitive Function in APP/PS1 Mice by Suppressing Inflammation and Apoptosis." Mol Neurobiol, 2025;63(1):129. PMID: 41269410.

Sources & Citations

Studies were read from their PubMed records; regulatory sources are listed below, read October 3, 2026.

Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.

Last reviewed: 2026-10-05